Established in 1993, Huadong Medicine Co.,Ltd specializes in the production and sales of antibiotic, Chinese patent medicine, synthetic drug, genetic engineering drugs, as well as wholesale business of Chinese and western medicine, Chinese herbal medicines, medical apparatus and instruments. The company is a large comprehensive listed pharmaceutical company integrated with pharmaceutical R&D, pharmaceutical industry, pharmaceutical distribution, retail, pharmaceutical logistics, and  undertakes the task of special drug storage of the state, provincial and municipal governments. The company successfully issued 50 million A-shares on the Shenzhen stock exchange in December 1999. ( Stock abbreviation: Huadong Medicine; stock code: 000963). At present, the registered capital of the company is 14.58 million yuan. The company and its main subsidiaries have more than 8,000 employees. In 2017, the company realized operating revenue of 27.832 billion yuan. Net profit attributable to shareholders of listed companies was 1.480billion yuan.

The company’s main business is pharmaceutical industry production, sales and pharmaceutical commercial operations. The core subsidiary in pharmaceutical industry, Hangzhou Sino-US Huadong Pharmaceutical Co. Ltd, is one of the top 50 pharmaceutical industries in China. It is also a national high-tech enterprise, a state-level innovation-oriented enterprise, a national intellectual property demonstration enterprise, a national intellectual property advantage enterprise and one of the top 100 technological innovation enterprises in Zhejiang province. Sino-US Huadong's annual sales exceeded 6 billion yuan in 2017. The company is a leading enterprise in the research, development and production of organ transplantation and diabetes drugs in China.

For the aspect of pharmaceutical business, the company is the largest and strongest comprehensive large pharmaceutical commercial enterprise in Zhejiang province, whose business covers a wide range of industries including pharmaceutical business operation, retail, supply chain management and big health industry. The company has a complete Zhejiang province business network and a deep penetration of the grass-roots terminal market network, and has a highly automated medical logistics center in Zhejiang and eastern China. The company's pharmaceutical business has been among the top ten pharmaceutical commercial enterprises in China for many years. Pharmaceutical commercial sales scale and market share in Zhejiang province rank first.

Over the years, the company has been highly recognized by China's mainstream media and capital markets for its sound business performance and good governance. The company has won the grand prize in various competitions of listed companies: "Top 100 on China's main board listed companies", “ China's listed companies investor relations selection Tianma award — best the board of directors award”, “ Top 20 most competitive listed pharmaceutical companies in 2017”, “ Top 150 on the investment value of Jinniu in 2016”; In 2017, the company was selected as the Top50 listed company in Forbes Asia and the top 500 fortune China, ranking 252.

Centering on the development of medical business, while creating economic benefits, the company has always adhered to the core values of "Cheshire, integrity, persistence and pragmatism" and made due contributions to the public health cause.